Clay Siegall, Ph.D., M.D., is one of the most fascinating individuals in cancer research today. This man has had a brilliant career that dates back to over 30 years. When it comes to fighting cancer progressively, it would very hard trying to find a more qualified medical professional than this. Dr. Siegall has first-hand knowledge of the disease itself because he watched his father struggle with it for years. Siegall just so happened to be in college during this time. Cancer treatments of the past eras were very harsh on the human body and Siegall wanted to find a more progressive way to treat the disease.
In 1998, Seattle Genetics came into existence, and this biotech company’s mission was to eradicate cancer. During the company’s earlier years, it struggled to stay a float. More money was being spent rather than being earned, which sent the company into a tailspin. Dr. Siegall, and his small team of medical associates put together a plan to get the company out of debt. By implementing a dynamic sales staff that promoted the company’s products, this extraordinary team started closing on seven-figure deals. As of today, Seattle Genetics has become one of the leaders in cancer research, and it has many successful drugs in its pipeline. Its flagship drug, ADCETRIS, has generated well-over $350 million in revenue since its inception of 2011. The company didn’t start earning huge sums of capital until 10 years after receiving its IPO.
Targeted-cancer therapies is the name of the game and no other cancer-research organization is doing it better. Dr. Siegall spends a lot of his time raising funds via public and private fundraising. In total, his actions have resulted in raising billions of dollars. All in all, this short article can’t do Clay Siegall any justice, but you should have a much better understanding of how important this man truly is.